FSS #36F79726D058E

Interim Agreement for Pharmaceutical Products via Federal Supply Schedule

This award represents an interim agreement executed under a Federal Supply Schedule contract vehicle, specifically Schedule 65 I B which covers drugs, pharmaceuticals, and hematology-related products. The recipient, Revolution Medicines, Inc., is a biopharmaceutical company engaged in developing innovative therapies, reflecting the company's capabilities to supply specialized pharmaceutical products under this procurement. The contract is significant for the awarding agency as it ensures continued, reliable access to essential pharmaceutical products necessary for healthcare and research needs. The scope of work involves the supply of drugs and related hematology products within a specified multi-month timeframe, ensuring uninterrupted availability through this federal acquisition channel. This agreement was awarded as an Indefinite Delivery Vehicle (IDV) under a federal supply schedule, facilitating streamlined procurement. The contract's performance period is set for approximately six months, commencing from early September 2026 with options for extension. No subcontractors, previous contracts, or solicitation details were disclosed, and no monetary obligations were indicated at award, suggesting this agreement establishes terms for potential future orders rather than immediate fulfillment.

Description

INTERIM AGREEMENT UNDER FSS SCHEDULE 65 I B DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS

View original record